3/27
08:15 am
lptx
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
High
Report
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
1/29
08:06 am
lptx
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $1.25 price target on the stock, down previously from $9.00.
High
Report
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $1.25 price target on the stock, down previously from $9.00.
1/29
08:06 am
lptx
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
High
Report
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
1/29
06:09 am
lptx
Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
High
Report
Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
1/29
06:09 am
lptx
Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
High
Report
Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
1/29
04:51 am
lptx
Leap Therapeutics downgraded to Neutral from Outperform at Baird
High
Report
Leap Therapeutics downgraded to Neutral from Outperform at Baird
1/29
04:51 am
lptx
Leap Therapeutics downgraded to Neutral from Outperform at Baird
High
Report
Leap Therapeutics downgraded to Neutral from Outperform at Baird